News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP
March 11, 2022
Wall Street Journal
Read Now
Press Release
Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP
March 11, 2022
Wall Street Journal
Read Now
News
Appointments and advancements
March 10, 2022
BioWorld
Read Now
Press Release
Appointments and advancements
March 10, 2022
BioWorld
Read Now
News
Management Tracks
March 10, 2022
BioCentury
Read Now
Press Release
Management Tracks
March 10, 2022
BioCentury
Read Now
Press Release
Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller
March 9, 2022
Read Now
Press Release
Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller
March 9, 2022
Read Now
News
Big Pharma is waking up to the booming field of gene editing. Here are the top 18 biotechs to know in 2022 that are poised to grab the drug industry's attention.
January 31, 2022
Business Insider
Read Now
Press Release
Big Pharma is waking up to the booming field of gene editing. Here are the top 18 biotechs to know in 2022 that are poised to grab the drug industry's attention.
January 31, 2022
Business Insider
Read Now